You are here

  • Home
  • Archive
  • Volume 9, Issue 11
  • Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2021 to July 2025

AbstractFullPdf
Nov 2021484490184
Dec 2021313315132
Jan 202213914396
Feb 202212312969
Mar 202214515289
Apr 202215016485
May 202216617881
Jun 202223224781
Jul 202217117853
Aug 202219120594
Sep 202219419775
Oct 202218518563
Nov 202214114262
Dec 202212613145
Jan 202310911349
Feb 202310610652
Mar 202311411555
Apr 2023767645
May 202310110132
Jun 2023909134
Jul 2023565634
Aug 2023575727
Sep 2023454518
Oct 2023959661
Nov 2023929233
Dec 2023686830
Jan 2024707140
Feb 2024696948
Mar 2024606132
Apr 2024777744
May 2024676836
Jun 2024404126
Jul 202410710942
Aug 2024676427
Sep 2024545545
Oct 2024585847
Nov 2024464747
Dec 2024636434
Jan 2025888875
Feb 2025555550
Mar 202510110270
Apr 202510410477
May 2025596058
Jun 2025454550
Jul 2025110
Total500051112527